UNSPSC 51141556: Eslicarbazepine

This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S5VXA428R4. European Medicines Agency schedules Eslicarbazepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB27751. Eslicarbazepine generally arises in the molecular formula C15H14N2O2. The term ESLICARBAZEPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 1, 2005, list 53.) Most nations schedule Eslicarbazepine under HS 29339930 and SITC 51577.

As of Q4 2014, ESLICARBAZEPINE remains the US FDA Preferred Term for this commodity. Eslicarbazepine bears US NLM identifiers UMLS ID C2725260 and NCI Concept Code C81473. SMILES: C1CCC2C(C1)C[C@@H](C3CCCCC3N2C(=O)N)O.

UNSPSC 51141556 Eslicarbazepine, a Commodity code, does not match the recent state and local opportunities associated with it. The code nominally designates a specific anticonvulsant pharmaceutical ingredient, but the three most recent solicitations posted under this code involve naloxone procurement, direct-to-manufacturer prescription program capability assessment, and multi-source generic pharmaceuticals and OTC products. None of these opportunities explicitly require eslicarbazepine. The mismatch suggests either a cataloging error in the source data or a broad tagging of pharmaceutical-procurement opportunities to this code regardless of specific active ingredients. The code shows little relevant recent activity for eslicarbazepine specifically.

The recent opportunities that are tagged to this code span state health agencies, county health departments, and cooperative purchasing consortia. Seminole County, Florida issued an IFB (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission released an RFI (posted April 3, 2026) exploring vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with contract effectiveness July 1, 2026. Geographic activity centers on Florida, Texas, and the MMCAP consortium states. Business development professionals should verify the accurate UNSPSC coding for eslicarbazepine-specific opportunities before pursuing procurement under this code designation.